Last updated: 2 months ago
Sanofi 6-K Filing: FDA Review for Dupixent & Strategic Deal with CD&R
Explore Sanofi's latest 6-K report detailing FDA's priority review for Dupixent and a key share purchase agreement with CD&R, highlighting strategic growth and compliance.